🇺🇸 FDA
Pipeline program

Valemetostat Tosylate, Valemetostat Tosylate

DS3201-A-U202

Phase 2 small_molecule active

Quick answer

Valemetostat Tosylate, Valemetostat Tosylate for Relapsed/Refractory Peripheral T-Cell Lymphoma is a Phase 2 program (small_molecule) at Daiichi Sankyo Europe GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Daiichi Sankyo Europe GmbH
Indication
Relapsed/Refractory Peripheral T-Cell Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials